Since the disclosure of the results of the third quarterly report of listed pharmaceutical companies, the pharmaceutical and biological industry has attracted much attention
from institutions.
In the past five trading days (November 16 to November 22), the pharmaceutical and biological industry has become an industry for institutional research, with a total of 23 pharmaceutical companies surveyed, of which more than 300 institutions have been surveyed
.
In the past 5 trading days, 23 pharmaceutical companies have been investigated by institutions! (Image source: Pharma Network)
Judging from the pharmaceutical stocks investigated by institutions in the past 5 days, Gibel has attracted the attention of institutions, with the number of institutional researchers as high as 301, including China Re Asset, CSC, CICC, China Europe Fund, etc
.
In the exchange session, the company's views on the recent downward revision of the diagnostic threshold of hypertension and whether the company's varieties face the risk of centralized procurement have attracted much attention
from institutions.
Gibel said that the diagnostic criteria for hypertension diseases may have different views, but it also reflects that all walks of life are gradually increasing their attention to hypertension
, a chronic disease.
At present, the awareness, treatment rate and control rate of hypertension in China are still low, and there is still a lot of room for improvement in the future, and the popularization of hypertension knowledge still has a long
way to go.
At the same time, the company's product nitrolol tablets is the country's first compound antihypertensive new drug, the company has complete intellectual property rights, and the relevant invention patents are still within the protection period
.
Under the current centralized procurement policy, it is expected that the possibility of nitranolol tablets being included in centralized procurement during the patent protection period is very small, and the entry of other hypertension drugs into centralized procurement will not form a hindrance
to the promotion of nitranolol tablets.
From a medium to long-term perspective, Gibel believes that nitrolol tablets as a superior product in the segment of hypertension with high heart rate, and the future market prospects are broad, and the company is very confident
about this.
At present, there are no similar products
in the market segment of hypertension with high heart rate.
In addition to Jibel, Teyi Pharmaceutical and Senxuan Pharmaceutical have been surveyed by more than 50 institutions, with 63 and 59 researchers respectively
.
Haier Biotechnology, Lude Medical, Price, and Xintian Pharmaceutical have all received more than 20 institutional attention
.
From the perspective of subdivision tracks, the above-mentioned pharmaceutical stocks that have received intensive attention from institutions in the past five trading days are mostly concentrated in popular tracks
such as traditional Chinese medicine, chemical drugs, APIs, and medical devices.
Among them, the head enterprise of traditional Chinese medicine, Teyi Pharmaceutical, has not only received high attention from 63 institutions, but also has a very bright market performance, the stock has risen in the past 5 trading days, during which the increase was as high as 39.
02%, and the new closing price was 31.
14 yuan
.
On November 17, Teyi Pharmaceutical accepted a survey of 10 institutions, and it was mentioned in the activity that in terms of respiratory cough and phlegm drugs, the company's advantageous proprietary Chinese medicine is the core product of Special Cough Suppressant Tablets
.
At present, the company has a special production workshop for cough tablets, the current production capacity is 1 billion pieces (about 40 million boxes), and in the later stage, according to market needs, in the existing place to increase production shifts or production equipment, the production capacity can reach 2.
4 billion pieces (equivalent to 100 million boxes).
In the future, the company will take cough tablets as the core to form a market competitive product group
focusing on phlegm and cough relief, heat and detoxification, antibacterial and anti-inflammatory drugs.
API stock Senxuan Pharmaceutical was surveyed by 59 institutions, and the stock rose 11.
20% in the past five trading days, and the new closing price was 11.
32 yuan
.
Recently, Jinghua Pharmaceutical, the parent company of Senxuan Pharmaceutical, replied to investors on the investor relations platform that Senxuan Pharmaceutical's ritonavir intermediates are mainly used in the synthesis
of ritonavir APIs.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
